“aimmune-therapeutics” Archives

in
Entry Author Date Location
Advisory Body Backs Aimmune Peanut Allergy Drug, Next Up: the FDA 09/13/19 San Francisco
FDA Doesn’t Shell Peanut Allergy Drug Pre-Hearing, Aimmune Shares Climb 09/11/19 San Francisco
DBV Rejoins Peanut Allergy Treatment Race, But Aimmune Takes the Lead 02/13/19 National
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More 01/25/19 National
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More 11/16/18 National
Bio Roundup: Meldonium Slip, Kratom Crackdown, Zinc Fingers & More 02/23/18 National
Aimmune’s Peanut Allergy Drug Hits Study Goals, FDA Filing Planned 02/20/18 San Francisco
15 For ’18: Key Clinical Data to Watch For Next Year (Part 2) 12/06/17 National
RA Capital Seeds Peanut Allergy Prevention Startup With $1.7M 06/01/16 Boston
Aimmune Prices Upsized $160M IPO, Climbs Higher in Debut 08/06/15 San Francisco
Page 1 of 1

Xconomy on Demand

Did you miss something? Don't despair…

Xconomy offers a number of ways to subscribe for free!

Subscribe Now
IDG Tech Network
Protected by Carbonite
Eventbrite - events made easy

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit/Ann Arbor, San Francisco, New York, Raleigh-Durham, Boulder/Denver, Texas, Wisconsin, Indiana, and beyond.

© 2007-2019, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Website development support from Andrew Koyfman with design support from Rob Hunter.